These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37771288)

  • 1. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
    Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
    Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Oct; 42(23):126043. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.
    Fridh AC; Palmborg A; Ta A; Freigofaite D; Warren S; Perdrizet J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2400751. PubMed ID: 39279284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK
    Vaccine; 2024 Sep; 42(22):126000. PubMed ID: 38845302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
    Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
    Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.
    Choi YH; Bertran M; Litt DJ; Ladhani SN; Miller E
    Lancet Public Health; 2024 Sep; 9(9):e654-e663. PubMed ID: 39153492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
    de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
    BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
    Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
    Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
    BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13.
    Rozenbaum MH; Huang L; Cane A; Arguedas A; Chapman R; Dillon-Murphy D; Tort MJ; Snow V; Chilson E; Farkouh R
    J Med Econ; 2024; 27(1):644-652. PubMed ID: 38577742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
    Lagoubi Y; Sfar MT; Gomez JA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.